Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 3Neoplasm Metastasis 2Colorectal Neoplasms 2Uterine Neoplasms 1Triple Negative Breast Neoplasms 1Recurrence 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Advanced Cancer 1

Interventions

Nivolumab 11Ipilimumab 6linrodostat 4relatlimab 3Pemetrexed 2tislelizumab 1regorafenib 1ralimetinib 1p38 Mitogen-Activated Protein Kinases 1mirdametinib 1gedatolisib 1figitumumab 1efatutazone 1abemaciclib 1Vorinostat 1Tetanus Toxoid 1Tamoxifen 1Sunitinib 1Ranitidine 1Midazolam 1LY2603618 1LY2584702 1Irinotecan 1Gemcitabine 1Fulvestrant 1Dasatinib 1Cyclophosphamide 1Crizotinib 1Cetuximab 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Advanced Cancer × gedatolisib × Clear all
NCT01347866 2018-10-29

Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer

Pfizer

Phase 1 Terminated
105 enrolled 64 charts

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡